bezafibrate has been researched along with Hypercholesterolemia in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (25.00) | 18.7374 |
| 1990's | 40 (58.82) | 18.2507 |
| 2000's | 11 (16.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anzivino, C; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Kienle, MG; Loria, P; Pellegrini, E; Ricchi, M; Zambianchi, L | 1 |
| Jokubaitis, LA | 2 |
| Matsuzawa, Y; Nagai, Y; Takemura, K; Yamashita, S; Yanagi, K | 1 |
| Bortolini, M; Farnier, M; Freudenreich, MO; Gonasun, L; Isaacsohn, JL; Salko, T; Troendle, AJ | 1 |
| Fisman, EZ; Motro, M; Tenenbaum, A | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldenberg, I; Leor, J; Mandelzweig, L; Motro, M; Schwammenthal, E; Tenenbaum, A | 1 |
| Esmat, AY; Gawad, SM; Ibrahim, AM; Mohamed, MA; Refaie, FM | 1 |
| Duriez, P; Fruchart, JC | 1 |
| Adler, Y; Behar, S; Benderly, M; Fisman, EZ; Goldbourt, U; Haim, M; Matas, Z; Tanne, D; Tenenbaum, A; Zimmlichman, R | 1 |
| Farine, JC; Vinazzer, H | 1 |
| Pöch, G | 1 |
| Canzler, H | 1 |
| Keller, M; Lang, PD; Middelhoff, G; Mordasini, R; Oster, P; Riesen, W | 1 |
| Mordasini, R; Oster, P; Riesen, W; Riva, G | 1 |
| Fringes, B; Riede, UN; von Deimling, O | 1 |
| Mertz, DP | 1 |
| Jespersen, B; Tvedegaard, E | 1 |
| Branchi, A; Fiorenza, AM; Rovellini, A; Sommariva, D | 1 |
| Arakawa, K; Bai, H; Hirata, K; Jimi, S; Liu, R; Saku, K; Sasaki, N; Zhang, B | 1 |
| Hess, OM; Seiler, C; Suter, TM | 1 |
| Espinosa, J; Fanghänel, G; Hernández, G; Macías, G; Martínez, L; Morales, M; Olivares, D; Sánchez, L; Valdés, E | 1 |
| Banks, D; Feher, MD; Foxton, J; Lant, AF; Wray, R | 1 |
| Akabane, S; Inoue, I; Ishii, J; Katayama, S; Kawazu, S; Negishi, K; Suzuki, M; Takahashi, K | 1 |
| Cummings, MH; Watts, GF | 1 |
| Armstrong, VW; Beil, FU; Eskötter, H; Greten, H; Keller, C; Klör, HU; Schneider, J; von Hodenberg, E; Weidinger, G; Weisweiler, P | 1 |
| Devuyst, O; Goffin, E; Pirson, Y; van Ypersele de Strihou, C | 2 |
| Forti, N | 1 |
| Luria, MH; Sapoznikov, D | 1 |
| Shepherd, J | 1 |
| Irsigler, H; Klein, W; Lechleitner, M; Patsch, JR; Sailer, S | 1 |
| Behar, S; Benderly, M; Boyko, V; Brunner, D; Graff, E; Reicher-Reiss, H; Shotan, A | 1 |
| Ector, H | 1 |
| Sterna, R | 1 |
| Gang, N; Langevitz, P; Livneh, A | 1 |
| Black, DM | 1 |
| Adachi, K; Azuma, C; Hayakawa, J; Ikegami, H; Kurachi, H; Matumoto, K; Morishige, K; Murata, Y; Nishio, Y; Node, K; Ohmichi, M; Tasaka, K | 1 |
| Mori, M; Nagai, T; Nakajima, K; Tomizawa, T | 1 |
| Chiodo, F; Manfredi, R | 1 |
| Cramb, R; Florkowski, CM | 1 |
| Autonell, J; Brugués, J; Kanterewicz, E; Riba, J; Sanmartí, R; Trias, I | 1 |
| Aviram, M; Brook, GJ; Hoffman, R | 1 |
| Anderson, DC; Arrol, S; Bhatagnar, D; Durrington, PN; Ishola, M; Mackness, M; Winocour, PH | 1 |
| Ditschuneit, HH; Ernst, E; Hehr, R; Hombach, V; Koenig, W; Kuhn, K; Rosenthal, J | 1 |
| Bruckert, E; De Gennes, JL; Truffert, J | 1 |
| Kudlacek, P; Sinzinger, H; Virgolini, I | 1 |
| Charleson, H; French, JK; Lewis, GR; Lintott, CJ; Maling, TJ; Nye, ER; Reuben, S; Scott, RS; Sharpe, DN; White, HD | 1 |
| Bo, M; Bonino, F; Fabris, F; Gottero, M; Molaschi, M; Neirotti, M; Pernigotti, L | 1 |
| Ansoleaga, J; Joven, J; Masana, L; Vilella, E | 1 |
| Frishman, WH; Kahn, S; Zimetbaum, P | 1 |
| Barcina, C; Cuesta, L; Fernández, E; Lázaro-Carrasco, E; Navarro, A; Rivera, G; Rodríguez Padial, L; Sánchez Domínguez, J | 1 |
| Alberts, AW; Beil, FU; Beisiegel, U; Eckardt, HG; Greten, H; Karkas, JD; Liou, R; Schrameyer-Wernecke, A; Till, AE | 1 |
| Shapiro, DR; Walker, JF | 1 |
| Jankelow, D; Myburgh, DP; Neutel, JM; Smith, DH | 1 |
| Bergmann, S; Fischer, S; Fücker, K; Gehrisch, S; Hanefeld, M; Jaross, W; Lang, PD; Leonhardt, W | 1 |
| Cramb, R; Florkowski, CM; Hughes, EA; Jones, AF | 1 |
| Blasi, F; Cosentini, R; Fasoli, A; Sommariva, D; Trinchera, M | 1 |
| Kłosiewicz-Latoszek, L; Mirkiewicz, E; Naruszewicz, M | 1 |
| Caslake, MJ; Cruickshank, A; Demant, T; Kilday, C; Lorimer, AR; Packard, CJ; Series, JJ; Shepherd, J | 1 |
| Bojanovski, D; Bojanovski, M; Canzler, H; Jochim, A; Schulzeck, P | 1 |
| Bard, JM; Devulder, B; Douste-Blazy, P; Fruchart, JC; Harvengt, C; Lecerf, JM; Leclerc, V | 1 |
| Weisweiler, P | 1 |
| Bergmann, S; Fischer, S; Hanefeld, M; Jaross, W; Lang, PD; Leonhardt, W | 1 |
| Holler, HD; Lang, PD; Müller, S; Steinhagen-Thiessen, E | 1 |
| Lösch, W; Neugebauer, G; Platt, D; Vömel, T | 1 |
| Branzoli, U; Carganico, G; Chiari, A; Cozzi, P; Lovisolo, PP; Severino, D | 1 |
9 review(s) available for bezafibrate and Hypercholesterolemia
| Article | Year |
|---|---|
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Niacin; Probucol; Risk Factors | 1994 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, HDL; Clofibric Acid; Coronary Artery Disease; Fenofibrate; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Liver; PPAR alpha; Randomized Controlled Trials as Topic; Triglycerides | 2006 |
Mechanism of action of fibrates.
Topics: Apolipoproteins B; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Receptors, LDL | 1993 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Topics: Bezafibrate; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Indinavir; Lipids; Retrospective Studies; Ritonavir; Saquinavir | 2001 |
Approaches to the management of hypercholesterolaemia.
Topics: Bezafibrate; Bile Acids and Salts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Probucol | 1992 |
Bezafibrate induced rhabdomyolysis.
Topics: Aged; Bezafibrate; Female; Humans; Hypercholesterolemia; Hypertension; Indomethacin; Rhabdomyolysis | 1992 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides | 1991 |
30 trial(s) available for bezafibrate and Hypercholesterolemia
| Article | Year |
|---|---|
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1994 |
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Topics: Aged; Bezafibrate; Blood Glucose; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Insulin; Life Tables; Male; Middle Aged; Myocardial Infarction; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
[Behavior of high-density lipoproteins in drug lipid-lowering treatment].
Topics: Adult; Apoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibric Acid; Colestipol; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Male; Middle Aged; Probucol | 1982 |
Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Cholesterol; Delayed-Action Preparations; Diet; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pravastatin; Receptors, LDL; Simvastatin | 1995 |
High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Drug Combinations; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Male; Middle Aged; Probucol; Time Factors | 1995 |
Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Tolerance; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Middle Aged; Safety; Triglycerides | 1995 |
Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.
Topics: Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Male; Middle Aged; Pravastatin | 1994 |
Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipids; Male; Middle Aged; Treatment Outcome | 1994 |
[Reductions in lipid fraction plasma levels induced by simvastatin and bezafibrate. Brazilian multicenter study].
Topics: Bezafibrate; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Middle Aged; Program Evaluation; Time Factors | 1993 |
[Effectiveness, tolerance and safety of simvastatin in comparison with bezafibrate in treatment of hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
Fluvastatin in combination with other lipid-lowering agents.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Niacin; Randomized Controlled Trials as Topic | 1996 |
Low total cholesterol is associated with high total mortality in patients with coronary heart disease. The Bezafibrate Infarction Prevention (BIP) Study Group.
Topics: Adult; Aged; Bezafibrate; Cause of Death; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Hypolipoproteinemias; Male; Middle Aged; Risk; Survival Analysis; Triglycerides | 1997 |
[The effect of hypolipemic treatment on the pharmacokinetics of propranolol].
Topics: Administration, Oral; Anticholesteremic Agents; Bezafibrate; Chromatography, High Pressure Liquid; Drug Interactions; Female; Humans; Hydroxylation; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Lovastatin; Male; Phenotype; Propranolol; Triglycerides | 1997 |
Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy.
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Hormone Replacement Therapy; Humans; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Postmenopause; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
Topics: Adolescent; Adult; Aged; Bezafibrate; Cholesterol; Diabetes Mellitus, Type 1; Double-Blind Method; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Middle Aged; Triglycerides | 1992 |
Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)?
Topics: Bezafibrate; Blood Viscosity; Delayed-Action Preparations; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemias; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Rheology; Single-Blind Method | 1992 |
[Comparison about the efficacy and tolerability between simvastatin and bezafibrate in the treatment of hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Bezafibrate; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
[Effect of bezafibrate in isolated hypercholesterolemia and mixed hyperlipidemia on infarct risk (Stepwise Program for Individual Risk Identification and Therapy): an open multicenter study].
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type V; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Factors; Triglycerides | 1991 |
Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, LDL; Cohort Studies; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; New Zealand; Simvastatin | 1991 |
Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Cholesterol; Female; Hemostasis; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
[The comparative treatment with lovastatin and bezafibrate of primary hypercholesterolemia. A randomized and double-blind trial].
Topics: Apolipoproteins A; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Humans; Hypercholesterolemia; Lovastatin; Spain; Triglycerides | 1991 |
Lovastatin versus bezafibrate: efficacy, tolerability, and effect on urinary mevalonate.
Topics: Adult; Aged; Bezafibrate; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Mevalonic Acid; Middle Aged; Single-Blind Method | 1990 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic | 1990 |
Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia.
Topics: Adult; Bezafibrate; Cholesterol; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Triglycerides | 1989 |
Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Topics: Adult; Aged; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1988 |
Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged | 1988 |
Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy.
Topics: Alkaline Phosphatase; Apolipoproteins A; Bezafibrate; Delayed-Action Preparations; Female; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Time Factors | 1988 |
Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemia.
Topics: Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Clinical Trials as Topic; Female; Humans; Hypercholesterolemia; Lipoproteins, VLDL; Male; Middle Aged; Random Allocation; Triglycerides | 1987 |
30 other study(ies) available for bezafibrate and Hypercholesterolemia
| Article | Year |
|---|---|
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Complement C4; Data Interpretation, Statistical; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Reference Standards; Simvastatin | 2008 |
Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
Topics: Adult; Bezafibrate; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Indoles; Male; Middle Aged | 2003 |
Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims.
Topics: Bezafibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Simvastatin | 2004 |
The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Cholesterol, Dietary; Diabetes Mellitus, Experimental; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Malondialdehyde; Quinazolines; Quinazolinones; Rats | 2005 |
C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease.
Topics: Aged; Angina Pectoris; Bezafibrate; Brain Ischemia; C-Reactive Protein; Cerebral Infarction; Female; Fibrinogen; Follow-Up Studies; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Israel; Life Tables; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Risk Assessment | 2006 |
Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia.
Topics: Aged; Anticoagulants; Benzenesulfonates; Bezafibrate; Cholesterol; Double-Blind Method; Drug Interactions; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type IV; Lipoproteins; Middle Aged; Platelet Adhesiveness; Triglycerides | 1983 |
[Initial values and drug effects].
Topics: Asthma; Bezafibrate; Blood Pressure Determination; Chlorthalidone; Cholesterol; Clenbuterol; Humans; Hypercholesterolemia; Hypertension; Indapamide; Placebos; Regression Analysis | 1984 |
[Drug therapy of hypercholesterinemias (author's transl)].
Topics: Adult; Bezafibrate; Cholestyramine Resin; Clofibric Acid; Colestipol; Dextrothyroxine; Fenofibrate; Humans; Hypercholesterolemia; Neomycin; Nicotinic Acids; Sitosterols | 1980 |
Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Triglycerides | 1981 |
Bezafibrate treatment in primary hypercholesterolaemia. Possibility of intermittent treatment.
Topics: Animals; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Mice; Microbodies; Rats; Time Factors | 1982 |
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle Aged | 1980 |
Bezafibrate induced reduction of renal function in a renal transplant recipient.
Topics: Bezafibrate; Humans; Hypercholesterolemia; Kidney Diseases; Kidney Transplantation; Male; Middle Aged | 1995 |
Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate.
Topics: Bezafibrate; Cholesterol; Coronary Angiography; Coronary Disease; Coronary Vessels; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Physical Exertion; Vasodilation | 1995 |
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
Topics: Adult; Aged; Aspartate Aminotransferases; Bezafibrate; Cohort Studies; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome.
Topics: Administration, Oral; Bezafibrate; Bilirubin; Colestipol; Gilbert Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Liver; Liver Function Tests; Lovastatin; Male; Middle Aged; Pravastatin; Pyrazines; Simvastatin | 1994 |
Hypercholesterolemia treatment in a renal transplant patient.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin | 1994 |
Creatinine rise after fibrate therapy in renal graft recipients.
Topics: Bezafibrate; Clofibric Acid; Creatinine; Female; Fenofibrate; Fibric Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Kidney Transplantation; Male | 1993 |
Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience.
Topics: Aged; Bezafibrate; Cholesterol, HDL; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Niacin; Triglycerides | 1993 |
Low total cholesterol and high total mortality in patients with coronary heart disease.
Topics: Bezafibrate; Coronary Disease; Humans; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Patient Selection; Survival Analysis | 1997 |
Relapsing acute pancreatitis induced by re-exposure to the cholesterol lowering agent bezafibrate.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Bezafibrate; Drug Hypersensitivity; Female; Humans; Hypercholesterolemia; Multiple Organ Failure; Pancreatitis; Recurrence | 1999 |
Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients.
Topics: Albuminuria; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Bezafibrate; Blood Pressure; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Hypercholesterolemia; Hypolipidemic Agents; Insulin; Lipids; Male; Middle Aged; Pravastatin | 2000 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome | 1999 |
Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies.
Topics: Adult; Animals; Bezafibrate; Cells, Cultured; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Esterification; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipid Peroxidation; Lipoproteins, LDL; Macrophages; Male; Malondialdehyde; Mice; Middle Aged; Pravastatin; Vitamin E | 1992 |
Low density lipoprotein receptor levels and the response to dietary and pharmacological intervention in polygenic hypercholesterolemia.
Topics: Adult; Apolipoproteins B; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Humans; Hypercholesterolemia; Lymphocytes; Middle Aged; Receptors, LDL | 1991 |
Bezafibrate in the treatment of hypercholesterolaemia in post-menopausal women.
Topics: Adult; Aged; Bezafibrate; Coronary Disease; Female; Humans; Hypercholesterolemia; Menopause; Middle Aged | 1990 |
Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Female; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Male; Middle Aged | 1989 |
Modification of low density lipoproteins from hypertriglyceridemic patients by macrophages in vitro and the effect of bezafibrate treatment.
Topics: Adult; Bezafibrate; Cholesterol; Female; Humans; Hypercholesterolemia; Hypertriglyceridemia; In Vitro Techniques; Lipoproteins, LDL; Macrophages; Male; Middle Aged; Vitamin E | 1989 |
[Type IIa dyslipoproteinemia. Effects of simvastatin and bezafibrate on atherogenic and non-atherogenic lipoprotein particles].
Topics: Bezafibrate; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins; Lovastatin; Simvastatin | 1988 |
Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bezafibrate; Biological Availability; Delayed-Action Preparations; Female; Glomerular Filtration Rate; Humans; Hypercholesterolemia; Hyperlipoproteinemias; Male; Metabolic Clearance Rate; Middle Aged; Triglycerides | 1988 |
Ethyl 2-([5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalenyl]oxy)- 2-methylpropanoate as a new potent oxyisobutyrate hypolipidaemic with unusual features.
Topics: Animals; Bezafibrate; Chemical Phenomena; Chemistry; Cholesterol; Clofibrate; Diet; Hypercholesterolemia; Hypolipidemic Agents; Imidazoles; Lipoproteins, LDL; Male; Naphthalenes; Rats | 1987 |